ImmunityBio expands ANKTIVA approval
- FDA expands ANKTIVA approval to include BCG-unresponsive NMIBC with papillary-only tumors
- ANKTIVA plus BCG now covers 85% of NMIBC patients
- 62% of patients in trial achieved complete response
IBRX
ImmunityBio, Inc. SEC filings
Every EDGAR filing for ImmunityBio, Inc. (IBRX), newest first, with AI summaries and stories.
- Ticker
- IBRX
- CIK
- 1326110
- Sector
- Biotech and pharma
- Latest filing
- 4d
Next: earnings expected ~Nov 6 · 10-Q expected ~Nov 9 (deadline Nov 9)
Insider activity
No open-market insider buys in the last 30 days.
Also: 2 open-market sales ($1.1M), 1 grant or exercise.
Filings
8-KImmunityBio, Inc.IBRXLIVE 4ImmunityBio, Inc.IBRXLIVE 2 insider filings
Cheryl Cohen, insider filing for IBRX
Show all 2
- 4Insider filing for IBRX
- 4Insider filing for IBRX
Cheryl Cohen, reporting
144ImmunityBio, Inc.IBRXLIVE ImmunityBio, Inc. files Form 144
- Filer: Simon Barry J.
- 560,000 shares to be sold
- Aggregate market value: $7,657,760
Barry J. Simon
144ImmunityBio, Inc.IBRXLIVE Cohen Cheryl files Form 144 for IBRX
- Filer CIK: 0001529371
- Sale of 81,056 shares
- Date of sale: 10/02/2026
Cheryl Cohen
SCHEDULE 13D/AImmunityBio, Inc.IBRXLIVE Ownership stake disclosure by Cambridge Equities, LP (amended)
Cambridge Equities, LP, filed by
10-QImmunityBio, Inc.IBRXLIVE 8-KImmunityBio, Inc.IBRXLIVE 8-KImmunityBio, Inc.IBRXLIVE 4ImmunityBio, Inc.IBRXLIVE 2 insider filings
Cheryl Cohen, insider filing for IBRX
Show all 2
- 4Insider filing for IBRX
- 4Insider filing for IBRX
Cheryl Cohen, reporting
144ImmunityBio, Inc.IBRXLIVE Cheryl Cohen, planned sale of IBRX shares
Cheryl Cohen, reporting
4ImmunityBio, Inc.IBRXLIVE Christobel Selecky, insider filing for IBRX
Christobel Selecky, reporting
144ImmunityBio, Inc.IBRXLIVE Christobel Selecky, planned sale of IBRX shares
Christobel Selecky, reporting
144ImmunityBio, Inc.IBRXLIVE Christobel Selecky, planned sale of IBRX shares
Christobel Selecky, reporting
144ImmunityBio, Inc.IBRXLIVE Christobel Selecky, planned sale of IBRX shares
Christobel Selecky, reporting
4ImmunityBio, Inc.IBRXLIVE Barry J. Simon, insider filing for IBRX
Barry J. Simon, reporting
4ImmunityBio, Inc.IBRXLIVE 6 insider filings
Michael D Blaszyk, insider filing for IBRX
Show all 6
- 4Insider filing for IBRX
- 4Insider filing for IBRX
- 4Insider filing for IBRX
- 4Insider filing for IBRX
- 4Insider filing for IBRX
- 4Insider filing for IBRX
Michael D Blaszyk, reporting
8-KImmunityBio, Inc.IBRXLIVE 4ImmunityBio, Inc.IBRXLIVE Barry J. Simon, insider filing for IBRX
Barry J. Simon, reporting
144ImmunityBio, Inc.IBRXLIVE Barry J. Simon, planned sale of IBRX shares
Barry J. Simon, reporting
8-KImmunityBio, Inc.IBRXLIVE 10-QImmunityBio, Inc.IBRXLIVE 8-KImmunityBio, Inc.IBRXLIVE 8-KImmunityBio, Inc.IBRXLIVE 8-KImmunityBio, Inc.IBRXLIVE 4ImmunityBio, Inc.IBRXLIVE Patrick Soon-Shiong, insider filing for IBRX
Patrick Soon-shiong, reporting · CALIFORNIA CAPITAL EQUITY, LLC, reporting · +3 more
8-KImmunityBio, Inc.IBRXLIVE SCHEDULE 13D/AImmunityBio, Inc.IBRXLIVE Ownership stake disclosure by Cambridge Equities, LP (amended)
Cambridge Equities, LP, filed by
4ImmunityBio, Inc.IBRXLIVE Barry J. Simon, insider filing for IBRX
Barry J. Simon, reporting
4ImmunityBio, Inc.IBRXLIVE 6 insider filings
Regan J Lauer, insider filing for IBRX
Show all 6
- 4Insider filing for IBRX
- 4Insider filing for IBRX
- 4Insider filing for IBRX
- 4Insider filing for IBRX
- 4Insider filing for IBRX
- 4Insider filing for IBRX
Regan J Lauer, reporting
10-KImmunityBio, Inc.IBRXLIVE 144ImmunityBio, Inc.IBRXLIVE Christobel Selecky, planned sale of IBRX shares
Christobel Selecky, reporting
8-KImmunityBio, Inc.IBRXLIVE 8-KImmunityBio, Inc.IBRXLIVE 4ImmunityBio, Inc.IBRXLIVE 4 insider filings
Patrick Soon-Shiong, insider filing for IBRX
Show all 4
- 4Insider filing for IBRX
- 4Insider filing for IBRX
- 4Insider filing for IBRX
- 4Insider filing for IBRX
Patrick Soon-shiong, reporting · CALIFORNIA CAPITAL EQUITY, LLC, reporting · +3 more
8-KImmunityBio, Inc.IBRXLIVE